Immutep Ltd ADR

Immutep Limited is a clinical-stage biotechnology company based in Sydney, Australia, that develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its lead product candidate is eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism. The pipeline includes AIPAC-003, TACTI-003, an investigator-initiated Phase II trial of neoadjuvant efti, EFTISARC-NEO, INSIGHT-003, EOC 202, IMP761, IMP731, and ieramilimab/LAG525/IMP701. The company collaborates with Merck & Co., Inc., the Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. Formerly known as Prima BioMed Ltd, it changed its name to Immutep Limited in November 2017, was incorporated in 1987, and is based in Sydney, Australia.